Document Detail


Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis.
MedLine Citation:
PMID:  17707573     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The formation of new blood vessels, uncontrolled cell expansions and invasions are the common feature of cancer, neovascular inflammatory and ocular diseases, such as age-related macular degeneration (AMD). Short interfering RNA (siRNA) and short-hairpin RNA (shRNA) have recently helped extend our understanding of the mechanisms regulating angiogenesis and tumor developments. Moreover, the early success of these tools has reinforced the therapeutic hopes of preventing endogenous or exogenous gene translation. In vivo experiments using several animal tumor models and human pre-clinical trials augured many benefits to control protein expression and cell signaling. The high specificity of siRNA and shRNA to target a protein is crucial to design a new generation of therapeutic agents. At the present, several investigations are focused on the understanding of both gene function and the proof-of-concept for siRNA-mediated anti-angiogenesis. Taken together, in vitro and in vivo studies shed light on the efficiency of siRNA as a new alternative therapeutic agent.
Authors:
Réda Hadj-Slimane; Yves Lepelletier; Nicolas Lopez; Christiane Garbay; Françoise Raynaud
Related Documents :
16306713 - Analysis of recq gene transcript in fruiting bodies of basidiomycetous mushroom lentinu...
17988193 - Osteopontin small interfering rna protects mice from fulminant hepatitis.
14693383 - Activation of gene expression by triplex-directed psoralen crosslinks.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2007-07-06
Journal Detail:
Title:  Biochimie     Volume:  89     ISSN:  0300-9084     ISO Abbreviation:  Biochimie     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-10-08     Completed Date:  2008-02-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1264604     Medline TA:  Biochimie     Country:  France    
Other Details:
Languages:  eng     Pagination:  1234-44     Citation Subset:  IM    
Affiliation:
Université Paris Descartes, Faculté de Médecine, Laboratoire de Pharmacochimie Moléculaire et Cellulaire, 45 rue des Saints-Pères, 75270 Paris Cedex 06, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Models, Biological
Neoplasms / blood supply,  genetics,  therapy*
Neovascularization, Pathologic / genetics,  physiopathology,  therapy*
RNA, Small Interfering / genetics*
Signal Transduction / genetics,  physiology
Transfection
Vascular Endothelial Growth Factor A / antagonists & inhibitors,  genetics*
Chemical
Reg. No./Substance:
0/RNA, Small Interfering; 0/Vascular Endothelial Growth Factor A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of RAPD to detect sodium arsenite-induced DNA damage in human lymphoblastoid cells.
Next Document:  Indicators for managing biosolids in Ireland.